 HEIDELBERG, Germany, July 30, 2021 GLOBE NEWSWIRE -- Affimed N.V. Nasdaq: AFMD, a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today the publication of a comprehensive preclinical in vitro and in vivo data package of its innate cell engager ICE AFM24 CD16AEGFR in mAbs. The published data were the basis for the Investigational New Drug IND clearance for Affimeds ongoing Phase 12a study with AFM24 monotherapy in patients with EGFR expressing solid tumors. The preclinical data demonstrates AFM24s unique mechanism of action that harnesses the innate immune system to induce tumor cell killing via antibody-dependent cell-mediated cytotoxicity ADCC and antibody-dependent cell phagocytosis ADCP. 